Wells: Pharmacotherapy Handbook 8th Edition

Pharmacotherapy Handbook 8th Edition provides practitioners and students with the critical information necessary to support drug therapy decision making for more than 140 diseases and disorders. Featuring a convenient alphabetized presentation, this handy guide utilizes tables, texts, figures, and treatment algorithms to make the information readily accessible and easily understood.

The consistent chapter organization includes:

• Disease state definition
• Review of relevant pathophysiology
• Clinical presentation
• Diagnosis 
• Desired outcome
• Treatment
• Monitoring

The Treatment section usually includes nonpharmacologic therapy, drug selection guidelines, dosing recommendations, adverse effects, pharmacokinetic considerations, and important drug interactions.

Contents 

SECTION 1: BONE AND JOINT DISORDERS, Edited by Terry L. Schwinghammer

• 1. Gout and Hyperuricemia
• 2. Osteoarthritis
• 3. Osteoporosis
• 4. Rheumatoid Arthritis

SECTION 2: CARDIOVASCULAR DISORDERS, Edited by Terry L. Schwinghammer

• 5. Acute Coronary Syndromes
• 6. Arrhythmias
• 7. Cardiac Arrest
• 8. Dyslipdemia
• 9. Heart Failure
• 10. Hypertension
• 11. Ischemic Heart Disease
• 12. Shock
• 13. Stroke
• 14. Venous Thromboembolism

SECTION 3: DERMATOLOGIC DISORDERS, Edited by Terry L. Schwinghammer

• 15. Acne Vulgaris
• 16. Dermatologic Drug Reactions and Common Skin Problems
• 17. Psoriasis

SECTION 4: ENDOCRINOLOGIC DISORDERS, Edited by Terry L. Schwinghammer

• 18. Adrenal Gland Disorders
• 19. Diabetes Mellitus
• 20. Thyroid Disorders

SECTION 5: GASTROINTESTINAL DISORDERS, Edited by Joseph T. DiPiro and Terry L. Schwinghammer

• 21. Cirrhosis and Portal Hypertension
• 22. Constipation
• 23. Diarrhea
• 24. Gastroesophageal Reflux Disease
• 25. Hepatitis, Viral
• 26. Inflammatory Bowel Disease
• 27. Nausea and Vomiting
• 28. Pancreatitis
• 29. Peptic Ulcer Disease

SECTION 6: GYNECOLOGIC AND OBSTETRIC DISORDERS, Edited by Barbara G. Wells

• 30. Contraception
• 31. Menopause & Perimenopausal & Postmenopausal Hormone Therapy
• 32. Pregnancy and Lactation: Therapeutic Considerations

SECTION 7: HEMATOLOGIC DISORDERS, Edited by Cecily V. DiPiro

• 33. Anemias
• 34. Sickle Cell Disease

SECTION 8: INFECTIOUS DISEASES, Edited by Joseph T. DiPiro

• 35. Antimicrobial Regimen Selection
• 36. Central Nervous System Infections
• 37. Endocarditis
• 38. Fungal Infections, Invasive
• 39. Gastrointestinal Infections
• 40. Human Immunodeficiency Virus Infection
• 41. Influenza
• 42. Intraabdominal Infections
• 43. Respiratory Tract Infections, Lower
• 44. Respiratory Tract Infections, Upper
• 45. Sepsis and Septic Shock
• 46. Sexually Transmitted Diseases
• 47. Skin and Soft-Tissue Infections
• 48. Surgical Prophylaxis
• 49. Tuberculosis
• 50. Urinary Tract Infections and Prostatitis
• 51. Vaccines, Toxoids, and Other Immunobiologics

SECTION 9: NEUROLOGIC DISORDERS, Edited by Barbara G. Wells

• 52. Alzheimer's Disease
• 53. Epilepsy
• 54. Headache: Migraine and Tension-Type
• 55. Pain Management
• 56. Parkinson's Disease
• 57. Status Epilepticus

SECTION 10: NUTRITIONAL DISORDERS, Edited by Cecily V. DiPiro

• 58. Assessment of Nutrition Status and Nutrition Requirements
• 59. Enteral Nutrition
• 60. Obesity
• 61. Parenteral Nutrition

SECTION 11: ONCOLOGIC DISORDERS, Edited by Cecily V. DiPiro

• 62. Breast Cancer
• 63. Colorectal Cancer
• 64. Lung Cancer
• 65. Lymphomas
• 66. Prostate Cancer
• 67. Renal Cell Carcinoma

SECTION 12: OPHTHALMIC DISORDERS, Edited by Cecily V. DiPiro

• 68. Glaucoma

SECTION 13: PSYCHIATRIC DISORDERS, Edited by Barbara G. Wells

• 69. Anxiety Disorders
• 70. Bipolar Disorder
• 71. Major Depressive Disorder
• 72. Schizophrenia
• 73. Sleep Disorders
• 74. Substance-Related Disorders

SECTION 14: RENAL DISORDERS, Edited by Cecily V. DiPiro

• 75. Acid-Base Disorders
• 76. Acute Kidney Injury
• 77. Chronic Kidney Disease
• 78. Drug Therapy Individualization for Patients with Chronic Kidney Disease
• 79. Electrolyte Homeostasis

SECTION 15: RESPIRATORY DISORDERS, Edited by Terry L. Schwinghammer

• 80. Allergic Rhinitis
• 81. Asthma
• 82. Chronic Obstructive Pulmonary Disease

SECTION 16: UROLOGIC DISORDERS, Edited by Cecily V. DiPiro

• 83. Benign Prostatic Hyperplasia
• 84. Erectile Dysfunction
• 85. Urinary Incontinence

APPENDICES, Edited by Barbara G. Wells

• Appendix 1: Allergic and Pseudoallergic Drug Reactions
• Appendix 2: Geriatrics
• Appendix 3: Drug-Induced Hematologic Disorders
• Appendix 4: Drug-Induced Liver Disease
• Appendix 5: Drug-Induced Pulmonary Disease
• Appendix 6: Drug-Induced Kidney Disease

Index

About the Author

• Barbara G. Wells, PharmD, FASHP, FCCP, BCPP, Dean and Professor, Executive Director, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, Oxford, Mississippi.
• Joseph T. DiPiro, PharmD, FCCP, Professor and Executive Dean, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, and University of South Carolina, Columbia.
• Terry L. Schwinghamamer, PharmD, FCCP, FASHP, FAPhA, BCPS, Professor and Chair, Department of Clinical Pharmacy, School of Pharmacy, West Virginia University, Morgantown, West Virginia.
• Cecily V. DiPiro, PharmD, Consultant Pharmacist, Mount Pleasant, South Carolina.

Product Details

• Paperback: 1176 pages
• Publisher: McGraw-Hill Medical; 8 edition (October 10, 2011)
• Language: English
• ISBN-10: 0071748342
• ISBN-13: 978-0071748346
• Product Dimensions: 8.2 x 4.7 x 1.9 inches

List Price: $55.00 

 

Moini: Comprehensive Exam Review for the Pharmacy Technician 2nd Edition with CD-ROM

Comprehensive Exam Review for the Pharmacy Technician 2nd Edition is an essential book for your students as they prepare to take the Pharmacy Technician National Certification Exam. Essential material summaries provide a concentrated review of the topics covered on the National Certification Exam. Chapters are completely reorganized for improved mastery of information, with each chapter ending with a multiple-choice quiz to reinforce the review material. Chapters are structured to help your students assess their knowledge of the topic areas covered on the exam. Eight comprehensive self-examinations, each with 120 questions, are written in the certification exam style to provide a realistic test-taking experience. Answers for all of the quizzes and tests are included at the back of the book to facilitate self-directed study. To provide even more practice for your students, Comprehensive Exam Review for the Pharmacy Technician 2nd Edition includes a CD-ROM with an additional 600 multiple-choice questions, along with the option to create an unlimited number of comprehensive exams.

Contents 

SECTION I: INTRODUCTION AND GENERAL KNOWLEDGE.

• 1. Pharmacy Technicians and Professional Organizations.
• 2. Pharmacy Law and Ethics for Technicians.
• 3. Pharmaceutical Terminology and Abbreviations.
• 4. Structures and Functions of Body Systems.
• 5. Common Disorders and Conditions.
• 6. Dosage Forms and Routes of Administration.
• 7. Pharmacy Calculations and Mathematics.
• 8. Biopharmaceutics and Factors Affecting Drug Activity.
• 9. Pharmacology Related to Various Body Systems.

SECTION II: ASSISTING THE PHARMACIST IN VARIOUS SETTINGS.

• 10. Safety in the Workplace.
• 11. Hospital Pharmacy.
• 12. Community Pharmacy.
• 13. Advanced Pharmacy.
• 14. The Roles and Duties of Pharmacy Technicians.
• 15. Sterile and Non-sterile Compounding.

SECTION III: ADMINISTRATION AND MANAGEMENT OF PHARMACY PRACTICE.

• 16. Policies and Procedures.
• 17. Management of Pharmacy Operations.
• 18. Financial Management and Health Insurance.
• 19. Computer Technology.
• 20. Inventory Control.

Appendices

• Appendix A: Pharmacy Technician Certification Examination.
• Appendix B: State Boards of Pharmacy.
• Appendix C: Professional Organizations.
• Appendix D: Vitamins.

Self-Examinations:

• Test I.
• Test II.
• Test III.
• Test IV.
• Test V.
• Test VI.
• Test VII.
• Test VIII.

Glossary.
Answer Keys.
Index.

Key Features

• The topics covered consist of essential material summaries highlighting key areas of pharmacology science, drug classifications, pharmaceutical calculation, and hospital and retail pharmacy.
• Each chapter provides a multiple choice quiz, with answers at the back of the book, to allow for focused self-assessment of specific topics.
• Includes a free CD-ROM that offers an additional six hundred multiple choice questions not found in the book.
• Contains photos, illustrations, figures and tables throughout the book that reinforce important concepts for your students.

New to this edition

• Reorganized into twenty chapters and consists of three sections, Introduction and General Knowledge, Assisting the Pharmacist in Various Settings, and Administration and Management of Pharmacy Practice.
• Contains five Appendices: Pharmacy Technician Certification Exam, State Boards of Pharmacy, Professional Organizations, Top 200 Prescription Drugs, and Vitamins
• Includes eight Self-Examinations, each containing one hundred twenty questions in the PTCB Exam format.
• Contains new chapters that include Structures and Functions of Body Systems, Common Disorders and Conditions, and Sterile and Non-sterile Compounding.

About the Author

• Jahangir Moini, M.D., M.P.H., C.Ph.T., is a professor of allied health programs at Everest University in Melbourne, Florida, where he established the medical assisting program in 1990 and the associate degree program for pharmacy technicians in 2000, as well as several other programs. He also served as director of allied health programs for 15 years and was director of the associate degree program for five years. In addition, Dr. Moini worked with the Brevard County Health Department as an epidemiologist and health educator consultant for 18 years, offering continuing education courses and updating nurses on new developments related to pharmacology, medication errors, immunizations, and other important topics. Today, he is actively involved in teaching and preparing students for service in various health professions, including roles as pharmacy technicians, medical assistants, and nurses. Since 1990, Dr. Moini has published many allied health books internationally. He holds a medical degree (M.D.) and a master's degree in public health (M.P.H.) and is a certified pharmacy technician (C.Ph.T.).

Product Details

• Paperback: 416 pages
• Publisher: Delmar Cengage Learning; 2 edition (January 1, 2011)
• Language: English
• ISBN-10: 1111128472
• ISBN-13: 978-1111128470
• Product Dimensions: 10.8 x 8.4 x 0.7 inches

List Price: $72.95 

 

Dressman: Oral Drug Absorption: Prediction & Assessment 2nd Edition with DVD

Ten years ago, the first edition of Oral Drug Absorption was published with the intent of closing the gap between gastroenterology textbooks on the physiology of the gastrointestinal (GI) tract and pharmaceutical textbooks on oral drug formulations. In the ensuing years, the field of oral drug absorption has evolved significantly on several fronts. First, there has been acceptance and increasing implementation of the biopharmaceutics classification scheme (BCS) concept, both at the regulatory and drug development levels. Second, application of biorelevant media to better understand active pharmaceutical ingredient (API) behavior in the GI tract has become widespread, not only for solubility and dissolution, but also for permeability applications. Third, the role of transporters in drug uptake across the GI mucosa has been recognized and is under intensive investigation. The same applies to drug metabolism in the gut wall, and within the next decade, we should be able to quantitatively describe both of these phenomena as they relate to prediction of API bioavailability. Fourth, our understanding of GI hydrodynamics and the availability of fluid in the various segments of the GI tract is slowly but surely improving. Fifth, there is a very strong interest in applying physiologically based pharmacokinetic (PBPK) modeling to oral drug absorption; this has become possible with the advent of sophisticated software programs like GastroPlus1 and PK-Sim1 and will surely become one of our most powerful tools in the years to come. And last but not least, the quality by design paradigm has aroused interest in new techniques to better link the composition and manufacture of oral drug products with their in vivo performance.

As a result of all these developments, it is high time to bring out a second edition of Oral Drug Absorption that captures the rapid progress in the field. In this edition, we start out with a chapter on the fundamentals of GI physiology— as it relates to oral drug absorption—and in the first section, we describe several aspects in more detail in chapters specifically addressing absorption mechanisms, GI motility, gut wall metabolism, food effects, and drug absorption in children and various disease states. The second section focuses on the BCS and the impact it is making on pharmaceutical R&D and regulation of oral drug products. Additionally, separate chapters are devoted to the measurement and interpretation of the key BCS parameters, solubility and permeability. The third section, entitled ‘‘Nonclinical Methods to Evaluate Oral Formulations,’’ first describes appropriate dissolution tests to characterize formulations in preclinical development—be they intended for immediate or controlled release in the GI tract. Then state of the art practice for formulation screening and development in the industry is recounted for immediate release products and for controlled release products. This section is wrapped up by a chapter devoted to implementation of PBPK modeling at the preclinical level. The last section turns attention to bioequivalence studies. Increasingly, alternatives to human pharmacokinetic studies are being used to obtain approval of generic drug products and to obtain continued approval for existing products when changes have been made to the composition or method of manufacture. The section is introduced with a chapter providing the fundamentals and current status of bioavailability and bioequivalence. The application of BCS and in vitro–in vivo correlation (IVIVC) to the proof of bioequivalence is then described in separate chapters, and the evolution of regulations pertaining to bioequivalence is put into global perspective. In recognition of the increased interest in application of IVIVC for proof of bioequivalence, we have also provided a CD, which shows the user how to generate IVIVCs utilizing an Excel spreadsheet. Numerous examples are given to illustrate the underlying theory and show how the IVIVC works, and it is hoped that this CD will become an integral part of the toolbox used by pharmaceutical scientists to facilitate formulation design and optimization on a day-to-day basis.

Of course, producing a new edition of a textbook requires the assistance of many people, and Oral Drug Absorption is no exception. We wish to thank Sandy Beberman and Sherri Niziolek for their untiring enthusiasm and support of this project. We are also indebted to the authors for their splendid efforts in preparing chapters that reflect state-of-the-art thinking in oral drug absorption. We also wish to thank our families for their support and understanding that books are largely created in the evenings and on weekends. Finally, we thank the readers of the first edition for the excellent feedback and stimulus to produce an updated version.

- The Editors -

Contents

Part I: Physiology of Oral Drug Absorption

• 1. Physiological Factors Affecting Drug Release and Absorption in the Gastrointestinal Tract
• 2. Drug Transport Mechanisms Across the Intestinal Epithelium
• 3. Gastrointestinal Transit and Drug Absorption
• 4. Gut Wall Metabolism
• 5. Food Effects on Drug Absorption and Dosage Form Performance
• 6. Oral Drug Absorption in Pediatric Populations
• 7. Gastrointestinal Disease and Dosage Form Performance

Part II: The Biopharmaceutics Classification System

• 8. The Biopharmaceutics Classification System: Recent Applications in Pharmaceutical Discovery, Development, and Regulation
• 9. Drug Solubility in the Gastrointestinal Tract
• 10. Permeability Measurement
• 11. BCS: Today and Tomorrow

Part III: Nonclinical Methods to Evaluate Oral Formulations

• 12. Dissolution Testing to Forecast In Vivo Performance of Immediate-Release Formulations
• 13. Dissolution Testing to Forecast the In Vivo Performance of MR Formulations
• 14. Modified-Release Dosage Forms: Formulation Screening in the Pharmaceutical Industry
• 15. Immediate Release Oral Dosage Forms: Formulation Screening in the Pharmaceutical Industry
• 16. Computer Models for Predicting Drug Absorption

Part IV: Bioequivalence Studies

• 17. In Vivo Bioequivalence Assessment
• 18. Biowaiving Based on the BCS—A Global Comparison
• 19. Biowaiving Based on In Vitro-In Vivo Correlation

Appendix

Index

Product Details

• Hardcover: 450 pages
• Publisher: Informa Healthcare; 2 edition (January 15, 2010)
• Language: English
• ISBN-10: 1420077333
• ISBN-13: 978-1420077339
• Product Dimensions: 9 x 6.2 x 1.1 inches

List Price: $229.95 

Bleavins: Biomarkers in Drug Development: A Handbook of Practice, Application & Strategy

In recent years, the topic of biomarkers has been featured at many specialized scientific meetings and has received extensive media coverage. We, the coeditors, felt that a book that approached the topic with an emphasis on the practical aspects of biomarker identification and use, as well as their strategic implementation, was missing and essential to improve the application of these approaches. We each have experience working with biomarkers in drug development, but we recognized that the specialized knowledge of a diverse group of experts was necessary to create the type of comprehensive book that is needed. Therefore, contributions were invited from authors who are renowned experts in their respective fields. The contributors include scientists from academia, research hospitals, biotechnology and pharmaceutical companies, contract research organizations and consulting firms, and the FDA. The result is a book that we believe will appeal broadly to pharmaceutical research scientists, clinical and academic investigators, regulatory scientists, managers, students, and all other professionals engaged in drug development who are interested in furthering their knowledge of biomarkers.

As discussed in Part I, biomarkers are not new: They have been used for hundreds of years to help physicians diagnose and treat disease. What is new is a shift from outcome biomarkers to target and mechanistic biomarkers, the availability of “ omics, ” imaging, and other technologies that allow collection of large amounts of data at the molecular, tissue, and whole - organism levels, and the use of data - rich biomarker information for “ translational research, ” from the laboratory bench to the clinic and back. Part II chapter is dedicated to highlighting several important technologies that affect drug discovery and development, the conduct of clinical trials, and the treatment of patients.

In Part III we ’ ve invited leaders from industry and regulatory agencies to discuss the qualification of biomarker assays in the fit - for - purpose process, including perspectives on the development of diagnostics. The importance of statistics cannot be overlooked, and this topic is also profiled in this part with a practical overview of concepts, common mistakes, and helpful tips to ensure credible biomarkers that can address their intended uses. Parts IV to VI present information on concepts and examples of utilizing biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine. Examples are drawn from a wide range of target - organ toxicities, therapeutic areas, and product types. We hope that by presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work.

Part VII focuses on “ lessons learned ” and the practical aspects of implementing biomarkers in drug development programs. Many pharmaceutical companies have created translational research divisions, and increasingly, external partners, including academic and government institutions, contract research organizations, and specialty laboratories, are providing technologies and services to support biomarker programs. This is changing the traditional organizational models within industry and paving the way toward greater collaboration across sectors and even among companies within a competitive industry. Perspectives from contributing authors representing several of these different sectors are presented in this part, as well as a legal perspective on potential intellectual property issues in biomarker development. The book concludes with Part VIII on future trends and developments, including developments in data integration, the reality of personalized medicine, and the addressing of ethical concerns. The field of biomarkers in drug development is evolving rapidly and this book presents a snapshot of some exciting new approaches. By utilizing the book as a source of new knowledge, or to reinforce or integrate existing knowledge, we hope that readers will benefit from a greater understanding and appreciation of the strategy and application of biomarkers in drug development and become more effective decision makers and contributors in their own organizations. 

Contents

PART I BIOMARKERS AND THEIR ROLES IN DRUG DEVELOPMENT

• 1 Biomarkers Are Not New
• 2 Biomarkers: Facing the Challenges at the Crossroads of Research and Health Care
• 3 Enabling Go/No Go Decisions

PART II IDENTIFYING NEW BIOMARKERS: TECHNOLOGY APPROACHES

• 4 Imaging as a Localized Biomarker: Opportunities and Challenges
• 5 Protein Biomarker Discovery Using Mass Spectrometry-Based Proteomics
• 6 Quantitative Multiplexed Patterning of Immune-Related Biomarkers
• 7 Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicity
• 8 Use of High-Throughput Proteomic Arrays for the Discovery of Disease-Associated Molecules

PART III CHARACTERIZATION AND VALIDATION

• 9 Characterization and Validation Biomarkers in Drug Development: Regulatory Perspective
• 10 Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development
• 11 Molecular Biomarkers from a Diagnostic Perspective
• 12 Strategies for the Co-Development of Drugs and Diagnostics: FDA Perspective on Diagnostics Regulation
• 13 Importance of Statistics in the Qualification and Application of Biomarkers

PART IV BIOMARKERS IN DISCOVERY AND PRECLINICAL SAFETY

• 14 Qualification of Safety Biomarkers for Application to Early Drug Development
• 15 Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug-Induced Systemic Mineralization: Case Study with a MEK Inhibitor
• 16 Biomarkers for the Immunogenicity of Therapeutic Proteins and its Clinical Consequences
• 17 New Markers of Kidney Injury

PART V TRANSLATING FROM PRECLINICAL RESULTS TO CLINICAL AND BACK.

• 18 Translational Medicine-A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkers
• 19 Clinical Validation and Biomarker Translation
• 20 Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritis
• 21 Pharmacokinetic and Pharmacodynamic Biomarker Correlations
• 22. Validating In Vitro Toxicity Biomarkers Against Clinical Endpoints

PART VI BIOMARKERS IN CLINICAL TRIALS.

• 23 Opportunities and Pitfalls Associated with Early Utilization of Biomarkers: A Case Study in Anticoagulant Development
• 24 Integrating Molecular Testing into Clinical Applications
• 25 Biomarkers for Lysosomal Storage Disorders
• 26 The Value Chain in the Development of Biomarkers for Disease Targets

PART VII LESSONS LEARNED: PRACTICAL ASPECTS OF BIOMARKER IMPLEMENTATION.

• 27 Biomarkers in Pharmaceutical Development: The Essential Role of Project Management and Teamwork
• 28 Integrating Academic Laboratories Into Pharmaceutical Development
• 29 Funding Biomarker Research and Development Through the Small Business Innovative Research Program
• 30 Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices
• 31 Anti-Unicorn Principle: Appropriate Biomarkers Don’t Need to be Rare or Hard to Find
• 32 Biomarker Patent Strategies: Opportunities and Risks

PART VIII WHERE ARE WE HEADING AND WHAT DO WE REALLY NEED?

• 33 IT Supporting Biomarker-Enabling Drug Development
• 34 Redefining Disease and Pharmaceutical Targets Through Molecular Definitions and Personalized Medicine
• 35 Ethics of Biomarkers: The Borders of Investigative Research, Informed Consent, and Patient Protection
• 36 Pathodynamics: Improving Biomarker Selection By Getting More Information From Changes Over Time
• 37 Optimizing the Use of Biomarkers for Drug Development: A Clinician's Perspective
• 38 Nanotechnology-Based Biomarker Detection

Index.

About the Authors

• MICHAEL R. BLEAVINS, PhD, is cofounder of Michigan Technology and Research Institute. He retired from Pfizer/Warner-Lambert/Parke-Davis in 2006 and has twenty-three years of experience in pharmaceutical research, development, and biomarkers with more than sixty-five peer-reviewed publications.
• CLAUDIO CARINI, MD, PhD, FRCPath, is Chief Medical Officer and Vice President for Clinical Research at Fresenius. Previously, Claudio served as Global Head of Translational Medicine at MDS and Global Head of Biomarkers at Hoffmann-La Roche. Claudio has more than twenty years of experience in the field of immunology and biomarkers and has authored more than 200 publications in international and domestic peer-reviewed journals.
• MALLÉ JURIMA-ROMET, PhD, is Senior Director for Development and Regulatory Services at MDS Pharma Services, where she provides strategic and scientific consulting to pharmaceutical and biotech sponsors, and leads drug development program teams. Mallé has authored over forty peer-reviewed publications and is an adjunct professor at the University of Montreal.
• RAMIN RAHBARI, MS, is cofounder and Senior Consultant at Innovative Scientific Management. Previously, Ramin has held positions at Pfizer, Synaptic, and Parke-Davis pharmaceutical companies, leading cross-functional biomarker teams.

 

Product Details

• Hardcover: 800 pages
• Publisher: Wiley; 1 edition (February 15, 2010)
• Language: English
• ISBN-10: 0470169273
• ISBN-13: 978-0470169278
• Product Dimensions: 6.5 x 1.6 x 9.2 inches

List Price: $169.00 

 

Woolley: A Guide to Practical Toxicology: Evaluation, Prediction and Risk 2nd Edition

The first edition of this book arose out of my perception that there is a large amount of toxicology lore that is widely accepted as fact and used in toxicological reports, but is not supported by easily accessible references. I also felt that there was a need for a practical, user-friendly introductory text for those coming to toxicology from related fields or professions, and who need some insight into how toxicity studies and investigations are carried out. I thought that the book should be informative but readable and should also act as a gateway to the subject, indicating where further information can be found, including the use of websites for literature searches and other areas, such as regulations and guidelines.

The book is set out as a guide on how to evaluate toxicity and then how to handle and use the data that are generated. After an introduction to the concepts of toxicology, the book takes the reader through the processes of toxicity testing and interpretation before looking at the concepts of hazard prediction and risk assessment and management. Two final chapters look at the evaluation of different chemical classes and at the future of toxicity testing and risk assessment. The audience for this book includes, new graduates starting careers in toxicology, those coming to the subject from different fields, and specialists in particular areas of toxicology who need some background on the other areas.

It is inevitable that as soon as a book hits the shelves (or screens), it will go out-of-date and the pressures of wanting to be up-to-date must be balanced against those to finish the manuscript on time. Suffice it to say that I was aware that the first edition lacked some areas that needed to be addressed, such as safety pharmacology, and would certainly need to be updated if ever a second edition became necessary. Accordingly, this new edition includes two entirely new chapters, one on safety pharmacology and one on the evaluation of different chemical classes. The chapter on alternatives has been completely rewritten and all the others have been reviewed and revised to a greater or lesser extent. The glossary has been expanded slightly and the index has been improved.

I acknowledge that there was some bias toward pharmaceuticals in the first edition in the treatment of the various subject areas. As I am largely a pharmaceutical toxicologist, this bias is still present to some extent; but I have attempted to write the book such that toxicologists in all areas of chemical evaluation may benefit from it. The basic principles of toxicology are common to all areas, whether you are evaluating pharmaceuticals or industrial chemicals. The main differences are in the regulatory guidelines addressed and in the philosophy required in each area; these differences are addressed in the new chapter on different chemical classes.

Throughout the book, words like “may,” “could,” and “however” appear frequently; this is tacit recognition that there are few certainties in life beyond the single gold standard that wherever a statement is made there will be someone to disagree with it. As with any walk of life, if a situation is seen as black and white, it simply means that the intervening shades of grey have not been discovered or are not understood. This is particularly true for any aspect or judgment or interpretation; differing opinions between toxicologists, especially toxicological pathologists, can be extremely frustrating for anyone needing a definitive answer to a question of safety. Getting a decision wrong in toxicology can be associated with far reaching adverse effects and with consequent litigation or (politically far worse) loss of votes. For this reason, toxicologists (especially those in regulatory agencies) tend to be conservative in their opinions; this is not necessarily a bad thing. However, conservatism is made more likely by poor, incomplete, or poorly understood data or results, which may lead to imposition of inappropriately restrictive exposure limits.

As I said in the preface to the first edition, the vastness of the subject means that this book cannot hope to be detailed or complete, for reasons of brevity and time. In view of this, the intention is to provide a basis of knowledge—a series of pointers—which can be expanded through use of the bibliography and references given. There are many different ways of achieving an objective in toxicological study and evaluation, and this book cannot pretend to address them all or to be absolutely definitive in any one area. Toxicologists are known for their differences in opinions and I am (still) just another opinionated toxicologist.

Toxicology is a dynamic subject with unique relevance to the public and, as a result, places heavy responsibility on the people who practice it, those who register or accredit toxicologists, and those who regulate or manage it. The future of toxicology is assured; the means of its future investigation is changing and it behoves us to think about what we are doing or what we are asking toxicologists to do (or, more importantly, not to do). As toxicologists, we should do nothing without thought, without considering the impact of our actions on the animals we use, on the public, or a host of other stakeholders. In many ways, if I cause the reader to think more about toxicology and its importance and impact on this world, I will have achieved one of my unwritten objectives.

- The Author -

 

Contents
1. Introduction to Toxicology: The Necessity of Measurement

• Introduction
• The Beginnings of Toxicological Measurement
• Toxicology and Toxicity Defined
• It is Natural So It Must be Safe - Everyday Toxicological Conundrums
• Natural Medicines and Poisons
• General Objectives of Toxicological Study
• Nature and Outcome of Toxic Reactions
• Cellular Basis and Consequences of Toxic Change
• Expression of Toxicity
• Target Organ Expression of Toxicity
• The Necessity for Toxicological Assessment
• Ethics of Toxicological Assessment
• The Three Rs: Reduce, Refine, and Replace

2. Normality: Definition and Maintenance

• Introduction
• What is Normality?
• Normality as a Range
• Experimental Normality
• Protocol Design and Procedure as Sources of Abnormality
• Control Groups as Normality
• Establishing and Maintaining Normality in Experimental Groups
• Baseline Data and Historical Controls

3. Determination of Toxicity: The Basic Principles

• Circumstances of Toxicity Testing
• Effects Sought in Toxicity Studies
• Basic Principles of Toxicological Investigation
• Toxicokinetic Design
• Regulatory Framework and Influences
• Regulation of Study Conduct - Good Laboratory Practice

4. Determination of Toxicity: In Vitro and Alternatives

• Introduction
• Rationale for In Vitro Toxicology
• How and When to Use In Vitro or Alternative Techniques
• Considerations in Screening Program Design
• Areas of Use of In Vitro Toxicology
• Considerations in the Development of In Vitro Tests
• Validation of In Vitro Methods
• Test Systems and Endpoints
• Toxicity in Silico
• Computer Prediction Systems
• Target Organ Toxicity
• Functional Toxicity Testing
• Pharmacology and Safety Pharmacology In Vitro
• Metabolism
• Kinetics
• Toxicity Testing
• Carcinogenicity
• Reproductive Toxicity
• Irritation and Corrosion
• Phototoxicity
• Ecotoxicology
• Pitfalls in In Vitro Toxicology
• Future Utility
• Overview

5. Safety Pharmacology

• Introduction
• General Principles
• Tests to be Conducted
• What to Test?
• Design
• Test Systems for Safety Pharmacology
• Safety Pharmacology in Toxicity Studies
• Tests and Their Conduct
• Pitfalls of Safety Pharmacology Studies
• Overview

6. Determination: General and Reproductive Toxicology

• General Toxicology
• Test Systems for General Toxicology
• Study Designs in General Toxicology
• Examinations for Specific Toxicities
• Pitfalls in General Toxicology
• Reproductive Toxicology
• Study Designs for Reproductive Toxicology
• Pitfalls in Reproductive Toxicology

7. Determination: Genotoxicity and Carcinogenicity

• Genotoxicity
• Carcinogenicity
• Pitfalls in Carcinogenicity Studies

8. Determination: Dermal Toxicity - Sensitization, Irritation, and Corrosion

• Introduction
• General Principles of Dermal Toxicology
• Factors in Dermal Toxicity
• Test Systems
• Study Design and Parameters Measured
• Sensitization
• Pitfalls in Irritation and Sensitization

9. Determination: Environmental Toxicology and Ecotoxicology

• Introduction
• Relevance of Environmental Assessment to Chemical Development
• General Principles of Environmental Toxicology and Ecotoxicology
• Pollution, Routes of Entry, and Environmental ADME
• Factors in Testing for Environmental Effect
• Test Systems and Study Types for Ecotoxicology
• Environmental Assessment of Agrochemicals
• Environmental Assessment of Pharmaceuticals
• Pitfalls in Environmental Toxicology

10. Interpretation: Basic Principles

• Introduction
• Steps in Interpretation
• Use of Background Data in Interpretation
• Statistics and Significance in Toxicology
• Assessing Exposure
• The Reality of Difference - The Interpretation of Small Differences
• The Reproducibility of Difference
• Overview of Interpretation

11. Interpretation: Different Data Types

• Individual Data Sets
• Safety Pharmacology
• General Toxicology
• Morphological Pathology
• Reproductive Toxicology
• Genotoxicity
• Carcinogenicity
• Environmental Toxicology and Ecotoxicology
• Case Studies
• The Fundamentals of Interpretation

12. Prediction of Hazard

• Introduction
• Principles of Prediction
• Steps in the Prediction Process
• Factors for Consideration in Prediction
• Prediction from Minimal Databases
• Computer Models for Toxicity Prediction
• Prediction for Individuals
• Prediction Summary

13. Background to Risk Due to Toxicity

• Introduction
• Overview of Risk Analysis
• Levels of Risk and Factors That Affect Risk
• Summary

14. Risk Assessment in Practice and Setting Exposure Limits

• Introduction
• Risk Assessment as a Process
• Data Quality
• Data Selection for Risk Assessment
• Single Effect Versus General Risk Assessment
• Tools and Models in Risk Assessment
• Target Population, Dose, and Exposure
• Process and Factors in Risk Assessment
• Setting Safety Factors and Margins
• Exposure Limits
• Dose Level Selection for Starting Risk Assessment
• Setting Exposure Limits
• Summary

15. Risk Assessment and Management in theWorkplace

• Introduction
• The Historical and Regulatory Background
• Classification and Exposure Limits
• Factors in Workplace Risk Assessment
• Workplace Risk Assessment
• Workplace Exposure Assessment
• Risk Management in the Workplace
• Overview

16. Risk Assessment: Carcinogenicity, The Environment, Evolution, and Overview of Risk Assessment

• Introduction
• Notes on Risk Assessment and Carcinogenicity
• Notes on Risk Assessment and The Environment
• International Management of Environmental Risks
• The Evolution of Risk Assessment
• Overview of Risk Assessment

17. Evaluation of Specific Classes of Chemical

• Regulatory Influences
• The Basic Toxicity Test Package
• Human Pharmaceuticals
• Veterinary Pharmaceuticals
• Medical Devices
• Agrochemicals/Plant Protection Products
• Biocides
• Cosmetics
• General and Industrial Chemicals—Reach
• Overview

18. The Future of Toxicity Testing and Risk Assessment

• Introduction
• Challenges for Toxicology
• Challenge for Risk Assessment and Management
• Influences on Toxicity Testing and Risk Assessment
• Utility of Animal Experiments in Risk Assessment
• Development of New Test Methods and Models
• In Vitro Toxicology and the Future
• Toxicology in Silico
• The Future of Safety Evaluation and Risk Assessment

Appendix: Useful Websites

Bibliography

Select Glossary

Index

About the Author

ADAM WOOLLEY is Director and Consultant Toxicologist, ForthTox Limited, Linlithgow, UK. He received his M.Sc. in Biochemistry from London University, London, UK. Mr. Woolley is a Fellow of the Royal College of Pathologists, London, UK, where he is an examiner in toxicology and is also a board member and Diplomate of the American Board of Toxicology. He is an Honorary Consultant at the School of Pharmacy and Pharmaceutical Sciences at Manchester University, Manchester and is a member of the British Toxicology Society and US Society of Toxicology. With over thirty five years of experience, including eighteen years in contract research and nine years in the pharmaceutical industry, Mr. Woolley is an expert in pharmaceutical development, including proteins and gene therapy agents, agrochemicals, human and veterinary pharmaceuticals, and industrial chemicals. He has conducted numerous toxicity studies, reviewed reports, and data packages, and is the author of the First Edition of Informa Healthcare’s A Guide to Practical Toxicology: Evaluation, Prediction, and Risk.

Product Details

• Hardcover: 472 pages
• Publisher: CRC; 2 edition (July 26, 2008)
• Language: English
• ISBN-10: 1420043145
• ISBN-13: 978-1420043143
• Product Dimensions: 9.1 x 6.2 x 1.1 inches

List Price: $69.95 

 

Greene: Pathology & Therapeutics for Pharmacists 3rd Edition: A basis for clinical pharmacy practice

The response to the previous editions of this text have been favourable, and it has clearly fulfilled a need of target audience. Since the last edition the important changes that have transformed pharmacotherapy are the rise of evidence based medicine (EBM) and the firm establishment of national and international therapeutic guidelines, usually based on careful meta-analyses of randomized controlled trials. These have frequently been issued by disease specific organizations such as the British Hypertension Society, or generic bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Prescribing Centre in the UK.

These guidelines have been incorporated into this edition wherever available, and have been a main focus of the update. However, as before, the overall intention remains to demonstrate how knowledge of the biomedical sciences of physiology, pathology and pharmacology underpins understanding of the rationale behind these recommendations.

The new edition will be as useful as the first two evidently have, and that it will continue to interest practitioners of disciplines outside the confines of pharmacy, reflecting the multidisciplinary nature of modern healthcare.

New to this edition 

• significantly reorganized and harmonized the sections and headings to improve consistency in structure and comprehension. These changes, together with a more detailed index, have enabled us to use an improved internal cross-referencing system.
• Where there are crossreferences within a chapter, the reader is directed to a closely-associated block of text or, if the reference is more remote, the page number is given.
• Cross-references outside a chapter give the chapter number, which together with the index should enable the material to be located quickly.
• Coverage of Thyroid disease in the Endocrine chapter have been added.
• A new chapter on Haematological disease.
• The use of drugs in renal impairment has been expanded in the Renal chapter.
• Evidence based therapeutic guidelines have been emphasized throughout.
• The References and further reading lists have been updated and rINNs are used throughout for drug nomenclature, following the BNF wherever possible.

Contents

• Dedication and acknowledgements
• with a note on drug nomenclature
• Preface to the third edition
• Extract from preface to the first edition
• About the authors
• Recommended reference sources
• Abbreviations
• Plate section between pages 854 and

PART 1 Basic strategy and introduction to pathology

1 Therapeutics: general strategy

• Terminology of disease
• Case history
• Drug disposition
• Drug selection
• References and further reading

2 Major pathological processes in disease

• Introduction
• Immunology
• Inflammation
• Ischaemia

PART 2 Body systems and their principal diseases

• 3 Gastrointestinal and liver diseases
• 4 Cardiovascular system
• 5 Respiratory diseases
• 6 Central nervous system
• 7 Pain and its treatment
• 8 Infections and antimicrobial therapy
• 9 Endocrine system
• 10 Neoplastic disease
• 11 Haematology
• 12 Rheumatology: musculoskeletal and connective tissue diseases
• 13 Skin diseases
• 14 Renal system

Index

About the Editors

Russell J. Greene, BPharm MSc PhD MRPharmS, Senior Lecturer in Clinical Pharmacy, Former Head, Pharmacy Practice Group, Department of Pharmacy, King’s College London, University of London, UK.

Dr Russell Greene gained his BPharm from Nottingham University in 1967 and did his pre-reg in Elizabeth Garrett Anderson hospital in London.

After working in hospital and community pharmacy in the UK and abroad he gained an MSc by research from Bath University in 1973 for a thesis on Drug administration in psychiatric hospitals.

Following a further spell abroad, including a year setting up a pharmacy training course at the University of the South Pacific in Fiji, in 1978 he became the Principal pharmacist for Education and training for the NWThames Regional Health Authority.

He joined Chelsea College in 1980 to teach clinical pharmacy and moved with it to King’s College in 1987. He gained his PhD in 1993 for a thesis on Prescription monitoring by community pharmacists and the role of medication records. He became senior lecturer in 1995 and

head of the Pharmacy Practice group in 1998. He was the MPharm Programme director until 2006, and his principal teaching responsibility has been organizing courses in pathology and therapeutics.

Norman D. Harris, BPharm PhD DIC, Emeritus Reader in Pharmaceutics, Department of Pharmacy, King’s College London, University of London, UK.

Dr Norman Harris entered Pharmacy in 1947 following National Service, having been an industrial chemist in metal processing and the food industry.

As apprentice at a very traditional London pharmacy, which dispensed for nearby embassies, he learned full-range extemporaneous dispensing, including suppositories, pessaries and silvered pills from prescriptions written in 1910!

At Chelsea School of Pharmacy he acquired the Chemist and Druggist and Pharmaceutical Chemist Diplomas, a BPharm degree, and won the Pharmaceutical Society’s Pereira Medal. A spell at Imperial College led to a PhD in Microbiology and the Imperial College Diploma and Fellowship of the Pharmaceutical Society followed in 1954.

On the staff at Chelsea, he taught Pharmacognosy (briefly), Pharmaceutics (Dispensing, Microbiology, Radiopharmacy), becoming Reader in Pharmaceutics and Head of Clinical Pharmacy, Honorary Pharmacist at Hammersmith Hospital and Chairman of the Oxford Region Pharmacy Advisory Committee. He was Post-graduate Tutor for the North-West Thames Region for many years and retired in 1984.

Product Details

• Paperback: 982 pages
• Publisher: Pharmaceutical Press; 3 edition (February 28, 2008)
• Language: English
• ISBN-10: 085369690X
• ISBN-13: 978-0853696902
• Product Dimensions: 9.7 x 7.5 x 2 inches

List Price: $82.50 

 

Rinzler: Controlling Cholesterol For Dummies 2nd Edition

Controlling Cholesterol For Dummies, 2nd Edition, doesn’t ask you to turn yourself into an anti-cholesterol fanatic — the kind of annoying person who sneers at other people’s dinner choices while acting superior about his own. (Actually, sneering and acting superior at the same time is a neat trick if you can do it. Just don’t try it on your friends at dinner.)

The goal with this book is to lay out the reasons why it makes sense to control your cholesterol and then present reasonable and moderate strategies to help you reach your goal.

Some of the information, like how to translate the cholesterol numbers you get on your annual physical, is simple. Other stuff, such as guidelines you can use to determine whether you’re a candidate for a heart attack — or for cholesterol-lowering medication — is more complex.

Throughout this book, the emphasis is on the idea that (here comes another catchy slogan) “Knowledge is power.” In this case, it’s the power to lower your cholesterol and reduce your risk of heart attack.

Contents at a Glance

• Introduction

Part I: Getting Up Close and Personal with Cholesterol

• Chapter 1: Mapping the Heart Land
• Chapter 2: Comparing Cholesterol’s Risks and Benefits
• Chapter 3: Rating Your Cholesterol-Related Risk

Part II: Eating Your Way to Lower Cholesterol

• Chapter 4: Writing Rules for a Cholesterol-Lowering Diet
• Chapter 5: Building a Cholesterol-Lowering Diet
• Chapter 6: Pinning Down the “How-To’s” For a Cholesterol-Lowering Diet

Part III: Leading a Cholesterol-Lowering Lifestyle

• Chapter 7: Weighing Weight’s Weight on Cholesterol
• Chapter 8: Exercising Options to Control Your Cholesterol
• Chapter 9: Weeding Out Tobacco’s Role in High Cholesterol
• Chapter 10: The Grape, the Grains, and Your Cholesterol

Part IV: Cutting Cholesterol with Nutrients and Medicine

• Chapter 11: Vitamins, Minerals, and Other Good Stuff
• Chapter 12: Prescribing Lower Cholesterol
• Chapter 13: Identifying Meds That Raise Cholesterol
• Chapter 14: Mouth-Watering Morsels for Special Occasions

Part V: The Part of Tens

• Chapter 15: Ten Clicks to Reliable Cholesterol Information
• Chapter 16: Ten Nutrition Web Sites
• Chapter 17: Ten Cholesterol  Myths
• Chapter 18: Ten (Okay, Eleven) “Eureka!” Cholesterol Moments

Appendix: Calories and Other Nutrients in Food

Index

About the Author

• Carol Ann Rinzler is the author of Nutrition For Dummies, now in its 4th edition, as well as Heartburn and Reflux For Dummies, and more than 20 other books on food and health. A former nutrition columnist for the New York Daily News, Carol lives in New York with her husband Perry Luntz, author of Whiskey and Spirits For Dummies, and their amiable cat, Katy.

Product Details

• Paperback: 360 pages 
• Publisher: For Dummies; 2 edition (April 28, 2008) 
• Language: English 
• ISBN-10: 0470227591 
• ISBN-13: 978-0470227596 
• Product Dimensions: 7.3 x 0.8 x 9 inches 

List Price: $21.99 

 

Nathan: Non-Prescription Medicines 4th Edition

In this book, OTC (over the counter) medicines currently available in the UK are reviewed in alphabetically arranged chapters on the conditions for which they are licensed to treat. This book will also be of value to pharmacists and other health professionals in the Republic of Ireland, because most of the proprietary branded medicines available in the UK are also available under the same name in Ireland. Also, patients from the UK, including from Northern Ireland, often ask for UK products, and these products are familiar as transnational advertising raises awareness. The classification of non-prescription medicines in Ireland is generally similar to that it in the UK, but due to licensing restrictions some medicines that are available without prescription in the UK are not in Ireland.

Information is provided on the following aspects of products:

• compounds or constituents,
• mode of action,
• indications,
• evidence of efficacy,
• side-effects,
• cautions and contraindications,
• interactions,
• dosage,
• presentations and formulations,
• products available and manufacturers (either all products in a category or, for categories where there are a large number of products, a representative selection),
• each section concludes with a summary of key points and suggestions for the most appropriate products to recommend.

Evidence of the efficacy of medicines is cited where it exists. However, few clinical trials on medicines for OTC use have been published, and most of the available evidence comes from the use of medicines as POMs before their reclassification to P status. In some instances, medicines are licensed for nonprescription use for different indications and at different doses from their use as prescription drugs, and caution may therefore be necessary in extrapolating clinical trial evidence to OTC use. There is very little clinical trial evidence for medicines that were already licensed for OTC use before POM-to-P reclassifications began. Such trials as could be found and appear to meet current methodological standards are cited.

This edition has been completely revised and brought up to date. New products have been included and assessed, and discontinued products have been deleted. New chapters on chlamydia obesity, and benign prostatic hyperplasia have been added.

A feature introduced with the last edition - the publication of 6-monthly updates on the Pharmaceutical Press website (www.pharmpress.com/onlineresources) - is continued with this edition.

- The Author -

Contents 

• 1 Acne
• 2 Athlete's foot
• 3 Benign prostatic hyperplasia
• 4 Cardiovascular medicines
• 5 Chlamydia (Chlamydia trachomatis infection)
• 6 Colds
• 7 Cold sores
• 8 Constipation
• 9 Corns and calluses
• 10 Cough
• 11 Cradle cap
• 12 Cystitis
• 13 Dandruff and seborrhoeic dermatitis
• 14 Diarrhoea
• 15 Dry skin
• 16 Ear problems
• 17 Emergency hormonal contraception
• 18 Eye conditions
• 19 Fungal nail infection (onychomycosis)
• 20 Haemorrhoids
• 21 Hay fever
• 22 Head lice
• 23 Indigestion
• 24 Insect bites and stings
• 25 Irritable bowel syndrome
• 26 Irritant and allergic dermatitis and mild eczema
• 27 Migraine
• 28 Motion sickness
• 29 Mouth ulcers
• 30 Nappy rash
• 31 Obesity management
• 32 Oral thrush
• 33 Pain
• 34 Pattern baldness
• 35 Premenstrual syndrome
• 36 Scabies
• 37 Smoking cessation products
• 38 Sore throat
• 39 Temporary sleep disturbance
• 40 Threadworm and roundworm
• 41 Vaginal candidiasis
• 42 Vaginitis and vaginal dryness
• 43 Verrucas
• 44 Warts
• Index

About the author

Alan Nathan has extensive experience of both community and academic pharmacy. He has been a locum, employee and proprietor community pharmacist, and for 15 years he was a lecturer in pharmacy practice at the Department of Pharmacy, King’s College London University. Since 2004, Alan has been a freelance pharmacy writer, publishing widely in pharmacy and other health profession journals and the consumer press. He has authored two books: this one and Fast Track: Managing symptoms in the pharmacy (Pharmaceutical Press, 2008). His main areas of writing interest are the management of minor ailments, and pharmacy law and ethics and professionalism. Alan has also been a consultant to several pharmacy organisations and companies. Alan was a member of the Council of the Royal Pharmaceutical Society from 1986 until 2002, and is co-founder and chairman of the Pharmacist Support Listening Friends stress help scheme for pharmacists.

Product Details

• Paperback: 308 pages
• Publisher: Pharmaceutical Press; 4 edition (June 2010)
• Language: English
• ISBN-10: 0853698864
• ISBN-13: 978-0853698869
• Product Dimensions: 9.1 x 6.1 x 0.8 inches

List Price: $55.00 

 

Hodgson: A Textbook of Modern Toxicology 4th Edition

There are some excellent general reference works in toxicology, including Casarett and Doull's Toxicology, 6th edition, edited by Curt Klaassen, and the 13 - volume Comprehensive Toxicology, the second edition currently being edited by Charlene McQueen, as well as many specialized monographs on particular topics. However, the scarcity of textbooks designed for teacher and student to use in the classroom setting that impelled us to produce editions 1 through 3 of this work is still apparent and the choice continues to be limited. The authors are, or have been, involved in teaching general toxicology at North Carolina State University and thus have insights into the actual teaching process and in the broader scope of toxicology as well as the subject matter of their areas of specialization.

Rapid advances are occurring in toxicology, particularly in the molecular and integrative aspects, and we hope these are refl ected in this textbook. As an aid to students and teaching faculty, we have added sample questions to each chapter. Answering these questions not only indicates that the material presented has been understood but is, in itself, a learning experience.

At North Carolina State University, we continue to teach a course in general toxicology (TOX801) that is open to graduate students and undergraduate upperclassmen. Our experience leads us to believe that this textbook is suitable, in the junior or senior year, for undergraduate students with some background in chemistry, biochemistry, and animal physiology. For graduate students, it is intended to lay the foundation for subsequent specialized courses in toxicology, such as those in biochemical and molecular toxicology, environmental toxicology, chemical carcinogenesis, risk assessment, and so forth.

We share the view that an introductory text must present all of the necessary fundamental information to fulfill this purpose, but in as uncomplicated a manner as possible. To enhance readability, references have been omitted from the text, although Suggested Reading or Bibliography is recommended at the end of each chapter.

As with previous editions, the amount of material and the detail with which some of it is presented, is more than is needed for the average general toxicology course. This, however, will permit each instructor to select and emphasize those areas they feel need particular emphasis. The obvious biochemical and molecular bias of some chapters is not accidental; rather, it is based on the philosophy that progress in toxicology continues to depend on further understanding of the fundamental basis of toxic action at the cellular and molecular levels. The depth of coverage of each topic represents that chapter author's judgment of the amount of material appropriate to the beginning level as compared to that appropriate to a more advanced course or text such as Smart and Hodgson, Molecular and Biochemical Toxicology, 4th edition (John Wiley and Sons, 2008).

- The Authors -

Key Features

• Adds chapters on new approaches to toxicology: molecular methods (-omics: toxicogenomics, proteomics, and metabolomics), bioinformatics, and systems biology.
• Now featured in the Fourth Edition are end-of-chapter questions.
• Provides a very thorough, concise and up-to-date summary of the most important topics within the toxicology field.
• Presents the interdisciplinary nature of toxicological studies.
• Continues from prior editions with coverage of basic concepts in toxicology and adds chapters on molecular methods (-omics: toxicogenomics, proteomics, and metabolomics), bioinformatics, and systems biology.
• Includes end-of-chapter questions.
• Online Solutions Manual available for academic adopters.
• Does not require an extensive background in anatomy and physiology.

Contents

PART I Introduction.

1 Introduction to Toxicology (Ernest Hodgson).

• 1.1 Definition and Scope.
• 1.2 Relationship to Other Sciences.
• 1.3 A Brief History of Toxicology.
• 1.4 Dose-Response Relationships.
• 1.5 Sources of Toxic Compounds.
• 1.6 Movement of Toxicants in the Environment.

2 Introduction to Biochemical and Molecular Methods in Toxicology (Ernest Hodgson, Gerald A. LeBlanc, Sharon A. Meyer and Robert C. Smart).

• 2.1 Introduction.
• 2.2 Cell Culture Techniques.
• 2.3 Molecular Techniques.
• 2.4 Immunochemical Techniques.
• 2.5 Proteomics.
• 2.6 Metabolomics.
• 2.7 Bioinformatics.
• 2.8 Summary and Conclusions.

PART II Classes of Toxicants.

3 Exposure Classes, Toxicants in Air, Water, Soil, Domestic and Occupational Settings (W. Gregory Cope).

• 3.1 Air Pollutants.
• 3.2 Water and Soil Pollutants.
• 3.3 Occupational Toxicants.

4 Classes of Toxicants: Use Classes (W. Gregory Cope and Ernest Hodgson).

• 4.1 Introduction.
• 4.2 Metals.
• 4.3 Agricultural Chemicals (Pesticides).
• 4.4 Food Additives and Contaminants.
• 4.5 Toxins.
• 4.6 Solvents.
• 4.7 Therapeutic Drugs.
• 4.8 Drugs of Abuse.
• 4.9 Combustion Products.
• 4.10 Cosmetics.

PART III Toxicant Processing In Vivo.

5 Absorption and Distribution of Toxicants (Ronald E. Baynes and Ernest Hodgson).

• 5.1 Introduction.
• 5.2 Cell Membranes.
• 5.3 Mechanisms of Transport.
• 5.4 Physicochemical Properties Relevant to Diffusion.
• 5.5 Routes of Absorption.
• 5.6 Toxicant Distribution.
• 5.7 Toxicokinetics.

6 Metabolism of Toxicants (Ernest Hodgson and Randy L. Rose).

• 6.1 Introduction.
• 6.2 Phase I Reactions.
• 6.3 Phase II Reactions.

7 Reactive Metabolites (Ernest Hodgson and Randy L. Rose).

• 7.1 Introduction.
• 7.2 Activation Enzymes.
• 7.3 Nature and Stability of Reactive Metabolites.
• 7.4 Fate of Reactive Metabolites.
• 7.5 Factors Affecting Toxicity of Reactive Metabolites.
• 7.6 Reactive Oxygen Species.
• 7.7 Examples of Activating Reactions.
• 7.8 Summary and Conclusions.

8 Chemical and Physiological Influences on Xenobiotic Metabolism (Andrew D. Wallace and Ernest Hodgson).

• 8.1 Introduction.
• 8.2 Nutritional Effects.
• 8.3 Physiological Effects.
• 8.4 Comparative and Genetic Effects.
• 8.5 Chemical Effects.
• 8.6 Environmental Effects.
• 8.7 Summary and Conclusions.

9 Elimination of Toxicants (Gerald A. LeBlanc).

• 9.1 Introduction.
• 9.2 Transport.
• 9.3 Renal Elimination.
• 9.4 Hepatic Elimination.
• 9.5 Respiratory Elimination.
• 9.6 Conclusion.

PART IV Toxic Action.

10 Acute Toxicity (Gerald A. LeBlanc).

• 10.1 Introduction.
• 10.2 Acute Exposure and Effect.
• 10.3 Dose-Response Relationships.
• 10.4 Non-Conventional Dose–Response Relationships.
• 10.5 Alternative Methods.
• 10.6 Mechanisms of Acute Toxicity.

11 Chemical Carcinogenesis (Robert C. Smart).

• 11.1 DNA Damage and Mutagenesis.
• 11.2 General Aspects of Cancer.
• 11.3 Human Cancer.
• 11.4 Classes of Agents That Are Associated with Carcinogenesis.
• 11.5 General Aspects of Chemical Carcinogenesis.
• 11.6 Oncogenes.
• 11.7 Tumor Suppressor Genes.

12 Teratogenesis (Jill A. Barnes and Ida M. Washington).

• 12.1 Introduction.
• 12.2 Overview of Embryonic Development.
• 12.3 Principles of Teratogenesis.
• 12.4 Mechanisms of Teratogenesis.
• 12.5 Future Considerations.

PART V Organ Toxicity.

13 Hepatotoxicity (Andrew D. Wallace and Sharon A. Meyer).

• 13.1 Introduction.
• 13.2 Susceptibility of the Liver.
• 13.3 Types of Liver Injury.
• 13.4 Mechanisms of Hepatotoxicity.
• 13.5 Examples of Hepatotoxicants.
• 13.6 Metabolic Activation of Hepatotoxicants.

14 Nephrotoxicity (Joan B. Tarloff and Andrew D. Wallace).

• 14.1 Introduction.
• 14.2 Factors Contributing to Nephrotoxicity.
• 14.3 Examples of Nephrotoxicants.
• 14.4 Summary.

15 Toxicology of the Nervous System (Bonita L. Blake).

• 15.1 Introduction.
• 15.2 The Nervous System.
• 15.3 Toxicant Effects on the Nervous System.
• 15.4 Neurotoxicity Testing.
• 15.5 Summary.

16 Reproductive System (Heather Patisaul).

• 16.1 Introduction.
• 16.2 The-Hypothalamic-Pituitary-Gonadal Axis.
• 16.3 Male Reproductive Physiology.
• 16.4 Disruption of Male Reproduction by Toxicants.
• 16.5 Female Reproductive Physiology.
• 16.6 Disruption of Female Reproduction by Toxicants.
• 16.7 Summary.

17 Endocrine Toxicology (Gerald A. LeBlanc).

• 17.1 Introduction.
• 17.2 Endocrine System.
• 17.3 Endocrine Disruption.
• 17.4 Incidents of Endocrine Toxicity.
• 17.5 Conclusion.

18 Respiratory Toxicity (James C. Bonner).

• 18.1 Introduction.
• 18.2 Anatomy and Function of the Respiratory Tract.
• 18.3 Toxicant-Induced Lung Injury, Remodeling and Repair.
• 18.4 Occupational and Environmental Lung Diseases.

19 Immune System (MaryJane K. Selgrade).

• 19.1 Introduction.
• 19.2 The Immune System.
• 19.3 Immune Suppression.
• 19.4 Classification of Immune-Mediated Injury (Hypersensitivity).
• 19.5 Effects of Chemicals on Allergic Disease.
• 19.6 Other Issues: Autoimmunity, and the Developing Immune System.

PART VI Applied Toxicology.

20 Toxicity Testing (Ernest Hodgson and Helen Cunny).

• 20.1 Introduction.
• 20.2 Experimental Administration of Toxicants.
• 20.3 Chemical and Physical Properties.
• 20.4 Exposure and Environmental Fate.
• 20.5 In Vivo Tests.
• 20.6 In Vitro and Other Short-Term Tests.
• 20.7 Ecological Effects.
• 20.8 Risk Analysis.
• 20.9 The Future of Toxicity Testing.

21 Forensic and Clinical Toxicology (Sharon A. Meyer and Bonita L. Blake).

• 21.1 Introduction.
• 21.2 Forensic Toxicology.
• 21.3 Clinical Toxicology.
• 21.4 Analytical Methods in Forensic and Clinical Toxicology.

22 Prevention of Toxicity (Ernest Hodgson).

• 22.1 Introduction.
• 22.2 Legislation and Regulation.
• 22.3 Prevention in Different Environments.
• 22.4 Education.

23 Human Health Risk Assessment (Ronald E. Baynes).

• 23.1 Introduction.
• 23.2 Risk Assessment Methods.
• 23.3 Noncancer Risk Assessment.
• 23.4 Cancer Risk Assessment.
• 23.5 PBPK Modeling.

Part VII Environmental Toxicology.

24 Toxicant Analysis (Chris Hofelt).

• 24.1 Introduction.
• 24.2 Environmental Sample Collection Methods.
• 24.3 Analytical Techniques.
• 24.4 Quantification, QA and QC.
• 24.5 Summary.

25 Basics of Environmental Toxicology (Gerald A. LeBlanc and David B. Buchwalter).

• 25.1 Introduction.
• 25.2 Environmental Persistence.
• 25.3 Bioaccumulation.
• 25.4 Toxicity.
• 25.5 Conclusion.

26 Transport and Fate of Toxicants in the Environment (Damian Shea).

• 26.1 Introduction.
• 26.2 Sources of Toxicants to the Environment.
• 26.3 Transport Processes.
• 26.4 Equilibrium Partitioning.
• 26.5 Transformation Processes.
• 26.6 Environmental Fate Models.

27 Environmental Risk Assessment (Damian Shea).

• 27.1 Introduction.
• 27.2 Formulating the Problem.
• 27.3 Analyzing Exposure and Effects Information.
• 27.4 Characterizing Risk.
• 27.5 Managing Risk.

Part VIII New Approaches in Toxicology.

28 Perspectives on Informatics in Toxicology (Seth W. Kullman, Carolyn J. Mattingly, Joel N. Meyer and Andrew Whitehead).

• 28.1 Introduction.
• 28.2 Transcriptomics.
• 28.3 Annotation Resources.
• 28.4 Genome Sequencing, Resequencing and Genotyping.
• 28.5 Epigenomic Profiling.
• 28.6 Computational Toxicology.
• 28.7 Informatics Tools in Toxicology.

29 Future Considerations (Ernest Hodgson).

• 29.1 Introduction.
• 29.2 Risk Assessment.
• 29.3 Risk Management.
• 29.4 Risk Communication.
• 29.5 In Vivo Toxicity.
• 29.6 In Vitro Toxicity.
• 29.7 Molecular and Biochemical Toxicology.
• 29.8 Development of Selective Toxicants.
• 29.9 Summary and Conclusions.

Glossary.

Index.

About the Author

• ERNEST HODGSON, PhD, is Distinguished Professor Emeritus of Toxicology at North Carolina State University. In addition to the previous editions of A Textbook of Modern Toxicology, he coedited Molecular and Biochemical Toxicology, Fourth Edition (Wiley) and its prior editions. Dr. Hodgson is the Editor of the Journal of Biochemical and Molecular Toxicology.

Product Details

• Hardcover: 672 pages
• Publisher: Wiley; 4 edition (June 21, 2010)
• Language: English
• ISBN-10: 047046206X
• ISBN-13: 978-0470462065
• Product Dimensions: 9.9 x 7.1 x 1.4 inches

List Price: $115.00